Helsinn Healthcare S.A. et al. v. Hospira Inc.

I'll research this case to provide a well-grounded overview. Let me start with several searches.

Let me dig deeper into the parallel litigation, IPRs, and the Supreme Court case.

Let me check the docket trajectory after the stay and any parallel IPR activity.

Helsinn Healthcare S.A. et al. v. Hospira, Inc., No. 1:15-cv-00264-GMS (D. Del.)

Parties: an innovator NDA holder (and its licensor) versus a generic injectables manufacturer. The plaintiff is Helsinn Healthcare S.A., a privately held, family-owned Swiss pharmaceutical group based in Lugano that holds NDA No. 021372 for Aloxi® (palonosetron hydrochloride injection), a 5‑HT₃ receptor antagonist used to prevent chemotherapy‑induced and post‑operative nausea and vomiting. Helsinn is not an NPE/PAE — it is an operating innovator company that in-licensed the palonosetron molecule and its intellectual property from Roche Palo Alto LLC in 1998, completed development, and holds the NDA; U.S. commercial rights run through Eisai Inc. (which acquired Helsinn's original U.S. partner MGI Pharma in 2008), with Eisai booking U.S. sales and co‑promoting with Helsinn Therapeutics U.S. Inc. (Eisai press release No. 15‑77, Nov. 17, 2015; D.N.J. opinion, Helsinn v. Hospira, Civ. No. 15‑2077 (MLC), Apr. 5, 2016). Roche Palo Alto LLC — a Delaware corporation with its principal place of business in California and the co‑assignee of the Aloxi® patents — was the second plaintiff, though it was terminated as a party on August 8, 2016 (CourtListener docket, No. 1:15‑cv‑00264). The defendant, Hospira, Inc., is a Delaware corporation headquartered in Illinois that describes itself as the world's leading provider of injectable drugs and infusion technologies; it filed the ANDA at issue and was acquired by Pfizer in September 2015 (Hospira continues as a Pfizer subsidiary). Hospira was represented in Delaware by Heyman Enerio Gattuso & Hirzel LLP (Dominick T. Gattuso, Aaron M. Nelson), with Chicago of‑counsel; Helsinn by Morris, Nichols, Arsht & Tunnell LLP (Jack B. Blumenfeld, Karen Jacobs, Maryellen Noreika) with Paul Hastings LLP of counsel (D.I. 40, Stipulation of Dismissal).

The accused product is Hospira's proposed generic palonosetron hydrochloride injection. Hospira filed its ANDA on April 30, 2014 seeking FDA approval to manufacture and market generic versions of Aloxi®, and its amended ANDA included a paragraph IV certification that the Orange Book patents were invalid and/or not infringed; Hospira mailed notice letters to Roche (California), Helsinn (Switzerland) and three law firms (D.N.J. opinion, Apr. 5, 2016; Helsinn v. Dr. Reddy's, 387 F. Supp. 3d 439 (D.N.J. 2016)). The resulting suit is a Hatch‑Waxman case under 35 U.S.C. § 271(e)(2)(A), where infringement is established by the act of filing the ANDA. The asserted family is the Aloxi® formulation patents, all claiming priority to a January 30, 2003 provisional and all listed in the Orange Book with expiration (including pediatric exclusivity) of July 30, 2024: the '724 and '725 patents claim a palonosetron intravenous formulation at a 0.05 mg/mL concentration (equivalent to a 0.25 mg dose in 5 mL) with EDTA and defined stability limits, for reducing emesis/CINV; the '424 patent (the patent named in the case metadata, U.S. Pat. No. 7,960,424) is a same-family formulation patent whose asserted claim (claim 6 in the parallel New Jersey case, and claims 2, 5 and 6 in earlier IPR papers) covers the 0.05 mg/mL palonosetron/EDTA formulation; the later-issued '219 patent (an AIA patent) expressly claims a fixed 0.25 mg dose of palonosetron in a 5 mL solution with EDTA and mannitol, stable at room temperature for 24 months; and the '094 patent is a further formulation patent from the same program. Caveat on scope: the case metadata for this docket lists only the '424 patent, but the docket's patent‑action report form (D.I. 4) lists 7,947,724; 7,947,725; 7,960,424 and DrugPatentWatch indexes all five patents ('724, '725, '424, '219, '094) for this docket — so the complaint almost certainly asserted the full Aloxi® family, with the '424 as the flagship formulation patent (drugpatentwatch.com litigation detail for 1:15-cv-00264; Justia transcript of D.I. 4).

Procedural posture: a Delaware protective filing stayed in favor of the first‑filed New Jersey action, then dismissed on settlement. The case was assigned to Judge Gregory M. Sleet (C.A. No. 15‑264‑GMS) in the District of Delaware and filed on March 25, 2015 — two days after Helsinn's first-filed action, D.N.J. No. 3:15‑cv‑02077, naming Hospira and its subsidiary Hospira Worldwide, Inc. Delaware mattered for two reasons. First, jurisdictionally: Hospira and Roche Palo Alto are both Delaware corporations, making Delaware an uncontroversial forum; the Delaware complaint was filed purely as a "protective measure" to preserve the automatic 30‑month FDA stay if the New Jersey action were dismissed for lack of personal jurisdiction. Second, as a practical matter, the District of Delaware is a preferred Hatch‑Waxman/ANDA venue with a deep bench on patent cases. Judge Sleet granted Helsinn's motion to stay the Delaware case on February 19, 2016, pending resolution of Hospira's motion to dismiss in New Jersey, holding that although forum-shopping concerns were "not unfounded" (and thus prejudicial to Hospira), the wastefulness of parallel proceedings, the early stage of the case, and Helsinn's representations that it would move to transfer the Delaware case to New Jersey made a stay appropriate (Richards, Layton & Finger case note, Mar. 1, 2016, rlf.com). The New Jersey court then denied Hosp

I'll research this case systematically across dockets, opinions, PTAB records, and press coverage.

Good leads. Let me dig into the docket, the parallel New Jersey action, and PTAB proceedings.

Let me pull the full Delaware docket and the New Jersey docket post-2016.

I'll research the counsel of record for the plaintiffs in this Delaware ANDA case.

Let me dig into the docket sheet and pro hac vice appearances for the Delaware case.

Counsel of Record for the Plaintiffs (Helsinn Healthcare S.A. and Roche Palo Alto LLC)

Important framing caveat: This Delaware action (C.A. No. 15-264-GMS) was a protective, second-filed case filed by Helsinn only to preserve the 30-month stay of FDA approval while its primary action against Hospira went forward in the District of New Jersey (D.N.J. No. 15-2077). Judge Sleet stayed it on February 19, 2016 (D.I. 36) and it was dismissed without prejudice on September 11, 2018 (D.I. 40–41). Because of the stay/dismissal, only a handful of attorneys ever entered an appearance in Delaware. The fuller Helsinn litigation team appeared in the New Jersey action, and I flag below which names are docket-confirmed in this case versus which are drawn from the parallel proceedings.

Confirmed Delaware counsel of record

CourtListener's party page lists Blumenfeld, Noreika, and Jacobs as the attorneys representing Helsinn Healthcare S.A./Roche Palo Alto in this docket (https://www.courtlistener.com/docket/[8206976](/patent/8206976)/parties/helsinn-healthcare-sa-v-hospira-inc/).

Non-resident (pro hac vice) counsel admitted in this case

Broader Helsinn team (appeared in the parallel D.N.J. actions, not confirmed on this Delaware docket)

These attorneys were the substantive drivers of the palonosetron litigation and are named in the related D.N.J. cases (15-cv-2077 and 15-cv-7378) and in Helsinn's Supreme Court briefing, but I could not confirm an entry of appearance by them in C.A. No. 15-264:

• Joseph M. O'Malley, Jr. – Paul Hastings LLP, New York (Helsinn's longtime outside counsel on the Aloxi® franchise).
• Eric W. Dittmann – Paul Hastings LLP, New York. His firm bio describes him as Helsinn's lead counsel in the Aloxi® Hatch-Waxman/PGR matters (including the Hospira litigation).
• Isaac S. Ashkenazi – Paul Hastings LLP, New York.
• Charles M. Lizza – Saul Ewing LLP (Wilmington/Newark). Identified as trial counsel of record for Helsinn and Roche Palo Alto in the New Jersey action (D.N.J. 15-2077); the D.N.J. papers state that Saul Ewing worked "together with Paul Hastings LLP and Loeb & Loeb LLP."

Notes / limits on sourcing

• No in-house counsel for Helsinn or Roche Palo Alto is identified on the docket; if an in-house attorney participated, they do not appear in the public record for this case. I will not infer one.
• The Delaware docket is short (roughly 42 entries) and the entire case was stayed from Feb. 2016, so most of the Helsinn trial team never formally appeared here — they litigated in Judge Cooper's New Jersey courtroom instead. If you need the definitive list of appearances in the Delaware action, the authoritative source is the CM/ECF docket for 1:15-cv-00264 (attorney list / D.I. 1, 29, 40); I did not find any sealed attorney list beyond the items cited.
• Firm/office attributions for Blumenfeld, Noreika, and Jacobs are from the docket's counsel block (Morris Nichols, Wilmington). Noreika's judicial status is public and post-dates her work here.

Bottom line: in this Delaware case, the plaintiffs' counsel of record were Morris, Nichols, Arsht & Tunnell (Blumenfeld, Noreika, Jacobs) as local/lead counsel, with Young J. Park of Paul Hastings admitted pro hac vice; the broader Paul Hastings team (O'Malley, Dittmann, Ashkenazi) led the underlying litigation but is docket-confirmed in the companion New Jersey actions rather than in Delaware.

I'll research the docket and counsel appearances. Let me run several searches.

Let me get the full Delaware docket with all attorney appearances and pro hac vice motions.

Let me pull the full docket sheet entries and check for any additional Hospira counsel (including pro hac vice).

Counsel of Record for Hospira, Inc. — Helsinn Healthcare S.A. v. Hospira Inc., No. 1:15-cv-00264 (D. Del.)

The Delaware docket as reflected in PACER/RECAP (CourtListener docket No. 8206976) and UniCourt's attorney listing shows only two attorneys ever appearing of record for Hospira in this case. Both were Wilmington, Delaware local counsel; there is one substitution during the case.

1. Dominick T. Gattuso — lead counsel of record (Delaware local counsel)

• Firm / office: Proctor Heyman & Enerio LLP (the firm also appears in contemporaneous filings as "Proctor Heyman Enerio LLP"; now Heyman Enerio Gattuso & Hirzel LLP), 300 Delaware Avenue, Suite 200, Wilmington, DE 19801. Tel. (302) 472-7300/7311; dgattuso@hegh.law.
• Role: Lead attorney per the CourtListener party record ("ATTORNEY TO BE NOTICED — LEAD ATTORNEY"). Entered on 15 Oct. 2015 via Notice of Substitution of Counsel (D.I. 14), stating "Entry of appearance of attorney Dominick T. Gattuso. Attorney Mary B. Matterer terminated." He signed Hospira's sealed answering brief and sealed declaration opposing Helsinn's motion to stay the second-filed Delaware case (D.I. 25–28, Dec. 2015–Jan. 2016) and STIPULATION filings thereafter.
• Experience note: Gattuso is a Delaware litigator with a deep ANDA/Hatch-Waxman and biopharma practice. He has represented Hospira in other D. Del. matters — notably Amgen Inc. v. Hospira, Inc., C.A. No. 15-839-RGA (EPO biosimilar § 271(e)(1) "safe harbor" case, tried 2017), where he signed Hospira's Rule 50(b)/Rule 59 renewed JMOL motion — and has served as Delaware counsel in numerous generic-drug actions (e.g., UCB v. Annora Pharma/Sunshine Lake with Winston & Strawn; Biogen v. Amneal).

2. Mary B. Matterer — initial Delaware counsel of record (substituted out)

• Firm / office: Wilmington, Delaware; the number listed on the docket, (302) 888-6800, is that of Morris James LLP (Wilmington), where Matterer practices in IP litigation. (Caveat: the CourtListener party field shows her phone/fax but truncates the firm field; I could not independently re-verify the firm name from a second source before hitting my search limit — treat the Morris James attribution as highly likely but not yet double-sourced.)
• Role: First Delaware counsel of record. She filed Hospira's Answer and Counterclaim (D.I. 7, 8 June 2015) and Rule 7.1 Disclosure Statement (D.I. 8). Per the docket she was terminated 16 Oct. 2015 when Gattuso's firm took over the representation.
• Experience note: A longtime Delaware IP litigator (Morris James) whose practice includes patent and Hatch-Waxman litigation; her role here was the initial local-counsel appearance before the defense team was reconstituted in the fall of 2015.

Cross-reference: parallel New Jersey action (different docket)

Hospira's lead defense team appears in the parallel, first-filed New Jersey case, Helsinn Healthcare S.A. v. Hospira, Inc., No. 3:15-cv-02077 (MLC) (D.N.J.), which controlled the litigation and prompted the Delaware stay. There, Hospira and Hospira Worldwide were represented by Arnold B. Calmann (lead), Jeffrey S. Soos, and Katherine Ann Escanlar of Saiber LLC, Newark, New Jersey (per VitalLaw's report of the 5 Apr. 2016 opinion and the D.N.J. docket). I flag this as a cross-reference, not a Delaware appearance — none of the Saiber attorneys appear on the 1:15-cv-00264 docket.

Explicit caveats / gaps

• No Hosspira-side pro hac vice appearances located. The only pro hac vice motion visible in the '264 docket excerpts is Helsinn's (for Young J. Park of Paul Hastings, D.I. 29, 6 Jan. 2016). I did not find any pro hac vice motion or appearance by Hospira's national/outside counsel in the Delaware docket. It is possible the out-of-state defense team coordinated behind the scenes (as they did in Amgen v. Hospira, where Willkie Farr & Gallagher handled the substantive briefing alongside Gattuso), but I cannot confirm those attorneys ever appeared in this case, and I will not name them here.
• Sealed filings. Several docket items are sealed or filed only in redacted form (e.g., D.I. 20/22, 25–28, 30–32), so the full certificate-of-service/counsel lists are not publicly readable.
• No in-house counsel identified. No Hospira/Pfizer in-house attorney appears of record. (Hospira was acquired by Pfizer in 2015; that corporate change is not reflected in any counsel appearance on this docket.)
• Docket coverage. My account rests on the PACER/RECAP entries surfaced through CourtListener, UniCourt, and DrugPatentWatch; if any appearance was filed but never captured by RECAP, it would not appear above. If you need certainty, the authoritative step is a fresh PACER pull of the full docket (all 42 entries) and the D.I. 14 substitution notice.

Bottom line: The only attorneys of record for the defendant, Hospira, Inc., in D. Del. 1:15-cv-00264 were Dominick T. Gattuso (Proctor Heyman & Enerio / now Heyman Enerio Gattuso & Hirzel — lead/local counsel, Oct. 2015–termination) and, before him, Mary B. Matterer (Wilmington local counsel, Mar.–Oct. 2015).